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Summary.-In the present study the tube LAI assay was used to monitor the isola-
tion of the TSA of 4 different types of human cancers. Each tumour antigen was
found to be specific for tumours arising in the organ from which the TSA wasinitially
derived and which were histopathologically similar. Immunochemical studies
revealed that these molecules co-isolate with normal human HLA antigens and are
associated with fl2m. On Sephadex G-150, the majority of the papain-solubilized
tumour antigen eluted in the mol. wt range 70,000-150,000. Analysis ofthis material
by SDS-PAGE and 6M guanidine-HCl column chromatography indicated that the
material is composed of smaller subunits with prominent peaks at 40,000, 25,000
and 12,000 mol. wt. Immunoadsorbent affinity chromatography of the solubilized
tumour-membrane constituents on AH-Sepharose-linked horse anti-human-fl2m
indicated that the tumour antigens, like HLA molecules, contain a /32m subunit.
The specificity ofbinding ofTSA tothe immunoadsorbent columns and the immuno-
logically specific abrogation of LAI reactivity were clearly shown. The present study,
therefore, indicates that by the isolation of fl2m, human tumour antigens can also be
Isolated, since human tumour antigens are associated with fl2m. Whether human
TSAs may perhaps be modified histocompatibility antigens remains to be answered.
Although the change upon malignant transformation inthe pattern ofthe cell-surface
proteins expressing the TSA determinant remains obscure, it would appear that for
tumours arising within a given organ, a consistent alteration of cell-surface proteins
occurs.
THE existence of individually unique
tumour-specific transplantation antigens
(TSTA) in the membranes of chemically-
induced tumours of experimental animals
has been unequivocally demonstrated by
both in vivo and by in vitro tests (Baldwin
and Barker, 1967; Old and Boyse, 1964).
TSTAs solubilized from tumour cell mem-
branes, either by limited papain digestion
or by hypertonic salt extraction from any
one tumour, have been heterogeneous
(Baldwin and Glaves, 1972; Holmes,
Kahan and Morton, 1970). Thomson and
Alexander (1973) purified papain-soluble
tumour-specific antigen (TSA) from a
chemically-induced rodent tumour, by
affinity chromatography with syngeneic
antiserum directed against the tumour,
and showed by reduction and alkylation
studies that the TSTAs were composed of
component polypeptide chains similar in
size to rodent histocompatibility antigens
(Thomson et al., 1976). In addition, studies
inothermurineandrodenttumoursystems
suggested that TSTAs from these tumours
also bear immunochemical and structural
similarities to normal histocompatibility
antigens (Bowen and Baldwin, 1975;
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Comoglio, Bestini and Forni, 1975; Good-
ing and Edidin, 1974; Invernizzi and Par-
miani, 1975; Ostberg et al., 1975).
In human tumours, the demonstration
of a host response to the tumour has
depended, in large part, on in vitro assays
of antitumour responses against putative
tumour-antigens. Halliday and Miller
(1972) discovered the phenomenon of
tumour-antigen-induced inhibition of
leucocyte adherence to glass. This leuco-
cyte adherence inhibition (LAI) assay is
based on the findings that nonsensitized
leucocytes from both cancer patients and
control subjects adhere to glass, whereas
leucocytes from cancer patients, but not
from control subjects, when mixed in
vitro with extracts of tumours arising in
the same organ and of the same histo-
logical type, undergo a loss oftheir normal
adherence to glass surfaces (Halliday et at.,
1975). Holan et al. (1974) described a
modified LAI assay in a rat model that
was performed in glass test tubes. In our
laboratory, we successfully adapted and
modified the glass test-tube assay (tube
LAI assay) and it was shown to be a
reliable, reproducible qualitative assay for
the detection of tumour antigen or of
specific antitumour immunity in patients
suffering from either breast cancer or
malignant melanoma (Flores et al., 1977;
Grosser et al., 1976; Grosser and Thomson,
1975; Grosser and Thomson, 1976; Marti,
Grosser and Thomson, 1976; Marti and
Thomson, 1976; Thomson et al., 1976;
Lopez and Thomson, 1977). Comparable
results in these and other tumour systems
have been found by other investigators
(Powell et al., 1975; Rutherford et al.,
1977; Leveson et al., 1977; Fujisawa,
Waldman, and Yonemato, 1977).
In the present study, the tube LAI
technique was used to monitor the isola-
tion of the putative tumour antigen from
4 histologically distinct human tumour
types. These tumour-cell constituents were
compared with each other for their
structural and immunochemical similar-
ities as well as for their immunochemical
and structural relationships to normal
HLA antigens with which they were co-
isolated.
MATERIALS AND METHODS
Tumour tissues
Malignant melanoma, breast and colon
adenocarcinoma and hepatoma tissues from
either surgery or necropsy were stored at
-40°C until processed. Initially, surgical
tumour-tissue specimens were used for the
preparation of both phosphate-buffered
saline (PBS, pH 7.3) tumour extracts, and for
the isolation ofthe putative tumour antigens.
Subsequently, tumour tissue from necropsy
specimens became the principal source of
material for isolation of tumour antigens,
since large quantities of tumour were needed
to isolate sufficient quantities of the required
material. The tumour tissue from necropsy
and surgical specimens had comparable
activity in the tube LAI assay.
Tube leucocyte adherence inhibition assay (tube
LAI assay)
The tube LAI assay was performed and the
results computed as previously described
(Flores et al., 1977; Grosser and Thomson,
1975; Marti and Thomson, 1976). Based upon
studies of a large number of patients with
breast cancer, malignant melanoma, and
control subjects with unrelated neoplastic
disease or non-cancerous diseases, a Non-
adherence Index (NAI*) of 30 or more has
been established as a positive LAI test with
either PBS-extracted tumours or papain-
solubilized tumour-antigen preparations
(Flores et al., 1977; Marti and Thomson,
1976; Thomson et at., 1976). The protein
content ofsamples was measured by the pro-
cedure of Lowry et al. (1951) with bovine
serum albumin as a standard.
"Blocking" tube LAI assay
The blocking tube LAI was performed as
previously described (Grosser and Thomson,
1976; Thomson, 1978). The isolated antigen
was diluted with 5% foetal calf serum (FCS)
in Medium 199 and 0 5 ml of this solution
was added to 1-3x 107 peripheral blood
leucocytes (PBL) suspended in 0 5 ml of
Nonadherent cells in presence of
specific antigen-nonadherent cells
* NAT in presence of nonspecific antigen x 100
Nonadherent cells in presence of
nonspecific antigen
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Medium 199. The PBL were from patients
with localized cancer ofthe breast, colon and
malignant melanoma who reacted in the tube
LAI against their respective cancer extracts.
The mixture was incubated for 30 min at
370C in a 5% C02 atmosphere, with frequent
agitation of the tubes. At the end of this
period, the cells were spun down, washed
twice with Medium 199, and plated separately
in glass test tubes with Medium 199 alone
and with the specific and nonspecific tumour
extracts. Specific antigen was accepted as
present in an isolate when the sample tested
was able to abrogate specifically the LAI
response of reactive leucocytes. An NAI
value of >30 was positive and indicated no
blocking, whereas an NAI value <30 was
negative and indicated blocking. All samples
were coded.
Isolation of LAI-reactive human tumour
antigens
Tumour-tissue membranes were prepared
as previously described (Thomson and
Alexander, 1973; Thomson et al., 1976). The
purified membranes were digested with 0 5
units papain/mg of membrane protein and
the papain-solubilized material was isolated
by sequential DEAE Sephadex A-50 and
Sephadex G-150 chromatography (87 x5 cm)
as previously described (Thomson etal., 1976).
The presence of tumour antigenic activity
in the isolated fractions were monitored by
tube LAI.
Physiochemical and immunochemical charac-
terization of isolated papain-solubilized tumour
membrane material
The isolated papain-solubilized material
was labelled with 1251 by the chloramine-T
method of Greenwood, Hunter and Glover
(1963). Molecular weight and subunit struc-
ture were estimated by Sephadex G-200
chromatography inguanidine HCI and sodium
duodecyl sulphate: polyacrylamide-gel elec-
trophoresis (SDS-PAGE).
Guanidine-HCl chromatography.-The
1251-labelled papain-solubilized membrane
material was adjusted to 6 M guanidine-HCl,
reduced with 0-1 M dithiothreitol for 6 h at
370C, and subsequently chromatographed by
ascending flow on a Sephadex G-200 column
(95 x 1-5 cm) equilibrated with 6 M guanidine-
HC1. The column had been previously
calibrated with protein standards that had
been reduced in an identical fashion.
SDS-PAGE.-The 125I-labelled papain-
solubilized membrane preparations were elec-
trophoresed on 10% SDS-tube gels by the
method ofWeber and Osborn (1969) or by the
discontinuous method of Laemmli (1970) in
12.5% SDS gels. The gels were then cut into
1-5 mm-thick slices that were counted
individually in a y-spectrometer. The protein
standards, bovine serum albumin (67,000
mol. wt), aldolase (40,000 mol. wt), pepsin
(35,000 mol. wt), chymotrypsinogen (25,000
mol. wt) and cytochrome C (12,400 mol. wt)
were always run simultaneously on a parallel
gel to calculate the apparent molecular
weights of the radio-labelled peaks. Unlabel-
led material along with protein mol. wt stan-
dards was also run in high resolution SDS
slab gels (0.75 mm thick) by the discontin-
uous method of Laemmli (1970) with the
modification that the running gel had a
continuous gradient of 5% to 20% poly-
acrylamide. The protein bands were stained
with 0.25% Coomassie Blue, 45% methanol
and 7.5% acetic acid.
Preparation of antisera.-Antiserum to
purified 92m (kindly supplied by Dr M. D.
Poulik) was prepared by immunization of
horses. The antiserum did not react with
normal human serum. By radioimmuno-
electrophoresis, the antiserum gave a single
band with the low-mol.-wt fraction of
serum or urine rich in J32m. In addition, the
antiserum was absorbed with normal human
serum coupled to Sepharose beads, to avoid
any possible reaction with human immuno-
globulins that may not be detected by preci-
pitation reactions in agar gel. The antiserum
for affinity chromatography was selected for
its low titre to make possible more efficient
elution from the affinity column.
An antiserum recognizing a common anti-
genic site on the heavy chain of the HLA
molecule was prepared as described by Cress-
well and Ayres (1976). The papain-soluble
HLA antigen was prepared from isolated
normal-liver cell membranes. The material
that eluted from a Sephadex G-150 column
in the mol. wt range -45,000 was then iso-
lated by horse anti-human-fl2m immuno-
absorbent affinity chromatography. The
bound fraction that was eluted from the
affinity column was enriched for fl2m and the
isolate was rechromatographed on a Sepha-
dex G-100 column. The fraction eluting in the
mol. wtrange -45,000 was used to immunize
rabbits. Antibodies to the fl2m subunit of
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HLA were then removed by solid-phase
immunoadsorption with purified /2m coupled
to AH-Sepharose 4B. The xenoantiserum
reacted with the cell surface of all nucleated
human blood cells, detected a constituent
present in all human tissues, and Nas shown
to co-cap with fl2m on the surface of PBL
similar to anti-HLA alloantigen sera. The
xenoantiserum to HLA showed cytotoxicity
for all lymphocytes but had no detectable
alloantigenic activity.
Xenoantiserum was raised to the papain-
soluble breast-cancer material isolated from
the horse anti-human-fl2m affinity column.
Rabbits were immunized by 3 i.m. injections
over 10 days with 250 ,ug of breast-cancer
material mixed with an equal quantity of
methylated bovine albumin and then emulsi-
fied in complete Freund's adjuvant. After
4 weeks they were boosted by an i.m. injec-
tion of 100 ytg of the same preparation in
incomplete Freund's adjuvant, and bled 1 and
2 weeks later. The xenoantiserum was
absorbed on normal human serum coupled to
AH-Sepharose 4B. By double immunodiffu-
sion, the absorbed xenoantiserum gave no
line of immunoprecipitation with papain-
soluble membrane material from cancers of
the breast or normal serum. By indirect
membrane immunofluorescence, the xeno-
antiserum at a dilution of 1:10 intensely
stained the membranes of single-cell prepara-
tions of breast cancer, other tumours and
lymphocytes. This antiserum preparation
was used for immunoprecipitation studies.
The antiserum was used in this form, since
absorption wNith liver- or spleen-cell mem-
branes removed all the staining activity for
breast-cancer membranes.
Antisera to non-fl2m cell-surface proteins
were raised in rabbits to papain-soluble
breast cancer and melanoma membrane
material that had not bound to the horse
anti-fl2m affinity column. The IgG derived
from the antisera was used unabsorbed in
affinity chromatography after coupling to
AH-Sepharose 4B. The antiserum raised in
rabbits to normal human serum (NHS) was
absorbed before use on an affinity column of
papain-soluble liver-cell membranes linked
to AH-Sepharose 4B.
Chromatography of the TSA on an anti-
human-/2m immunoadsorbent affinity col-
umn.-A horse anti-human-32m affinity-
chromatography column was prepared as
previously described (Thomson et al., 1976).
A column (35 x 2-5 cm) was packed with
170 ml AH-Sepharose 4B coupled to 4-5 g
of horse y-globulin isolated from specific
anti-human-32m serum by DEAE chroma-
tography. The fraction from the Sephadex
G-150 column with tumour antigen, as deter-
mined by tube LAI assay, or similarly pre-
pared control material, was applied to the
anti-92m immunoadsorbent affinity column
in PBS. After the unbound fraction had been
washed through with 10 column-volumes of
PBS the columns were prewashed with 1-0 m
NaCl, NaOH-glycine buffer, pH 9 0, to
remove nonspecifically absorbed proteins
(Zoller and Matzku, 1976). The specifically
bound material was then eluted with 3 0 M
KSCN. All procedures were performed at
4°C. The bound fraction was immediately
dialysed against PBS at 4°C and, after over-
night dialysis, the dialysed residue was
centrifuged at 75,000 g for 1 h and concen-
trated by ultrafiltration. The unbound frac-
tion was treated in an identical manner.
The 32m content in all the fractions
was measured by radioimmunoassay (Smith
et al., 1975). A double antibody radio-
immunoassay for HLA was used to detect
HLA as described by Cressw-ell and Ayres
(1976).
Specificity of anti-human-J32M immuno-
adsorbent column. Specificity of the horse
anti-human-182m immunoadsorbent affinity
column was shown as follows: albumin did not
bind to the anti-fl2m affinity column and was
quantitatively recovered inthe effluent. When
the immunoadsorbent was initially reacted
with fl2m and washed, and then human
serum albumin was passed through the
column, no 92m was detectable in the albu-
min wash by f2m radioimmunoassay, al-
though all of the albumin was recovered. If
the anti-J32m immunoadsorbent column was
overloaded with ,2m and washed, and then
,2M was again applied to the column, the
quantity of the ,2m recovered in the effluent
was equal to that applied. Hence, the P2m
binding showed marked specificity.
Prewashes ofthe affinity columns to remove
nonspecifically absorbed proteins with 1-0 M
NaCl, NaOH-glycine buffer, pH 9 0, failed to
remove any 32m activity in the prewash, and
the tumour antigen remained bound to the
affinity column (Zoller and Matzku, 1976). To
demonstrate further the specificity of 32m
binding, immunoadsorbent columns ofnormal
lgG from both humans and rabbits were
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prepared by covalently coupling the materials
to AH-Sepharose 4B.
In 1975, Reisfeld et al. (1975) reported that
the specificity of absorption of HLA antigen
to anti-J32m antibody sites by immuno-
adsorbent affinity chromatography is accept-
ably demonstrated by initially reacting the
immunoadsorbent with an excess of f2m,
thoroughly washing the column, thenincubat-
ing with HLA antigen for 4 h and showing
that no HLA antigen exchanges for the bound
/2m. Conversely, however, Robb, Strominger
and Mann (1976) showed more recently that
f2m displaced HLA on an anti-/2m affinity
column, and the columns were easily regen-
erated by acidic washes. In the experiments
reported here, studies were performed with 3
different affinity columns under the same
conditions described by Reisfeld et al. (1975)
to determine whether specificity of binding
could be shown by the method they had
described. With the anti-32m affinity column,
48% of 1251-/32m exchanged for bound and
unlabelled fl2m at the end of4 h incubation at
4°C. With a rabbit anti-rat-yG affinity
column, 47 0 of rat 1251-yG exchanged with
bound and unlabelled yG. Finally, with an
anti-CEA affinity column, 610 of 1251-CEA
exchanged with bound and unlabelled CEA.
By these experiments with 3 different
affinity columns, we were unable to repeat the
observations of Reisfeld et al. (1975) and we
miust conclude that the criteria described by
that group for the demonstration ofimmuno-
adsorbent specificity are certainly not uni-
versally applicable.
RESULTS
Each tumour used for isolation of TSA
was tested as a PBS extract in the tube
LAI assay against PBL from an appro-
priately reactive cancer patient and a
normal control subject. Fig. 1 shows the
number ofnon-adherent leucocytes from a
breast-cancer patient and a control subject
when incubated with various concentra-
tions of a PBS extract of either breast
cancer or hepatoma. At protein concentra-
tions of 100 to 150 ,ug/tube, the leucocytes
from the breast-cancer patient showed a
significantly greater degree of nonad-
herence in the presence of the breast-
cancer extract than of the hepatoma
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FIG. I.-Titration of PBS extracts of breast
cancer, melanoma and hepatoma against
leucocytes from reactive breast-cancer,
melanoma and hepatoma patients and from
control subjects. The average number of
nonadherent cells in triplicate tubes at
each dilution of tumour extract is shown.
The difference in leucocyte nonadherence
to two tumour extracts is expressed as the
nonadherence index (NAI).
extract. In contrast, the leucocytes from
the control subject showed almost equal
degrees ofnonadherence in the presence of
the tumour extracts at all protein con-
centrations (Fig. 1). The breast-cancer
patient had a positive NAI, whereas the
control subject had anegativeNAI. Identi-
cal results for the leucocytes from patients
with malignant melanoma and hepatoma,
with their corresponding tumour extracts
and appropriate controls, were noted (Fig.
1). Fig. 1 shows that the optimum tumour-
directed LAI response (NAI value) is
observed at 100 ,ug protein/tube, and as
previously observed (Flores et al., 1977;
Grosser et al., 1976; Grosser and Thomson,
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1975, 1976; Marti et al., 1976; Marti and
Thomson, 1976) does not have a quantifi-
able dose-response.
Chromatographic isolation of papain-solu-
bilized membrane tumour antigens
In previous studies, the,,PBS extract of
breast cancer was chromatographed on
Sepharose 4B and the antigenic activity
was shown to be present inthe void volume
(Grosser and Thomson, 1975). When puri-
fied tumour membranes from breast cancer
and melanoma were used as antigen in the
tube LAI assay, it was shown that the
leucocytes from patients with breast
cancer and melanoma had LAI reactivity
to the tumour membranes of the corres-
ponding histopathological type of tumour
(Thomson et al., 1976).
In the present study, when the isolated
tumour membranes were digested with
papain to yield a water-soluble tumour-
antigenpreparation,andthepapain-soluble
membrane material was chromatographed
on DEAE-Sephadex A-50 as an initial step
to remove highly charged materials,
especially DNA, tumour antigenic activity
was found in the unbound fraction and
notinthe boundfraction (datanot shown).
Up to 60% of the protein was lost in this
step (Table XI). The unbound fraction of
the papain-soluble breast-tumour material
was chromatographed on Sephadex G-150,
and Fig. 2 shows the 4 fractions that were
pooled for assay by tube LAI. The
fractions corresponded roughly to the
void volume (Fraction 1), the elution
volume ofaldolase (Fraction 2), the elution
volume of ovalbumin (Fraction 3) and the
elutionvolumeofribonuclease (Fraction 4).
In the melanoma preparations, the LAI
activity was present principally in Frac-
tions 1 and 2 (Table I). Thetumour antigen
or LAI activity of papain-soluble mem-
brane from breast cancer was also found
principally in Fractions 1 and 2 (Table II).
Such activity was occasionally found in
Fraction 3 although the activity recovered
was generally less than that found in
either ofFractions 1 or 2. Fig. 2 shows that
Fraction 2 represents material that elutes
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FIG. 2.-Sephadex G-150 chromatographic
pattern of the papain-soluble breast-cancer
membranes. The fractions were pooled as
shown and the total protein, P2m and
HLA content in each of the 4 fractions was
determined. The elution position of the
protein standards is indicated. When the
fractions are assayed by tube LAI with
leucocytes from reactive breast-cancer
patients the usual results are indicated.
in the mol. wt range 70,000-150,000,
whereas Fraction 3 includes material
eluting in the mol. wtrange 30,000-70,000.
Material with mol. wt <30,000, found in
Fraction 4, infrequently showed LAI
activity. Thus, the results indicate that
the papain-solubilized tumour-membrane
fractions that showed tumour-antigen
activity in the standard tube LAI assay
eluted principally in the mol. wt range
70,000-150,000 or >150,000 (Tables I
and II).
In the tube LAI assay, PBS extracts
are used as the standard antigen; hence,
in the initial experiments the papain-
solubilized material from the cancer-cell
membranes were used as the specific
antigen, and compared with the PBS
cancer extracts as the nonspecific antigens.
Tables I and II show that the isolated
papain-soluble cancermaterials canreplace
their equivalent PBS tumour extract and
retain immunological specific reactivity.
.: . i,
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TABLE I.-Papain-solubilized Melanoma
Membranes Chromatographed on Sepha-
dex G-150: Antigenic Activity Assayed
by Tube LAI.
TABLE II.-Papain-solubilized Breast Can-
cer Membranes Chromatographed on
Sephadex G-150: Antigenic Activity As-
sayed by Tube LAI.
Donor
Donor of of
melanoma leuco-
membranes cytest
1
2
3
4
5
Mel
Con
Mel
Con
Mel
Con
Mel
Con
Mel
Con
Mel
Con
NAI* Of
donor to
PBS
tumour
extract
100
3
52
-11
60
0
59
16
47
15
57
6
NAIt of
Sephadex G-150
chromatographie
fractions
A
1
105
28
60
15
56
-7
38
-4
20
-17
14
-6
2
97
8
59
-3
46
-4
90
-4
68
0
74
-3
3
29
-3
19
-6
25
-10
-2
-2
-14
-1
-18
-5
4
-16
-17
-12
-12
-11
-18
6
-14
31
19
35
23
*Nonadherence index (NAI) was calculated with
PBS extracts of melanoma as specific antigen and
of breast cancer as nonspecific antigen.
tNAI was calculated with the papain-soluble
melanoma fractions as the specific antigen and the
nonspecific antigen was a PBS extract of breast
cancer, except in Preparation 4 where the non-
specific antigen was papain-soluble bowel cancer
Fractions 1 and 2. The papain-soluble melanoma
fractions were tested at -100 jug/tube. The pre-
sence of LAI activity is indicated by an NAI value
of 30 or more.
:Melanoma patient (Mel) or Control subject (Con).
Subsequently, the differences in leucocyte
reactivity to the specific and nonspecific
antigens was compared when both anti-
genic materials were papain-solubilized
extracts of the cancer-cell membranes
isolated in an identical fashion (Tables I
and II).
The standard tube LAI was highly
dependent on protein concentrations.
When the protein concentration of the
PBS tumour extracts is below 50 jig/tube
in the standard tube LAI assay, the
number of nonadherent cells decreases
(Fig. 1) and the number of nonadherent
cells is often too few to consider the
counts statistically significant. Similar
results occurred when we tried to titrate
the isolated papain-soluble tumour anti-
gens to determine the least quantity of
material that had antigenic activity;
hence, quantitation of antigen activity
was not possible with the standard tube
Donor of
breast-
cancer
membranes
Donor
of
leuco-
cytest
I Br. Ca.
Con.
Br. Ca.
Con.
BeD Br.
Con.
2 Br. Ca.
Con.
Br. Ca.
Con.
Ben. Br.
Con.
3 Br. Ca.
Con.
Br. Ca.
Con
Br. Ca.
Con.
4 Br. Ca.
Con.
5 Br. Ca.
Con.
6 Br. Ca.
Con.
NAI* of
donor
to
PBS
tumour
extracts
36
16
50
20
15
5
114
19
97
_28
15
5
57
18
40
5
44
12
56
-8
113
18
49
13
NAIt of
Sephadex G-150
chromatographic
fractions
1 2 3 4
51 79 29 0
4 -27 5 -7
69 70 12 13
-5 -19 13 -8
14 -24 -1 -7
26 -5 10 -11
116 79 38 -5
-8 -18 10 -8
43 48 30 -2
4 -7 11 6
18 -15 -12 5
1 -4 3 12
34 39 14 7
-9 -16 2 15
30 33 22 -6
12 -8 14 -19
32 50 17 -2
6 -10 -1 -3
-2 43 11 -11
26 -13 -18 -20
9 54 44 5
7 17 3 -2
21 87 32 59
15 -24 14 23
*NAI was calculated with PBS extracts of breast
cancer as specific antigen and PBS extracts of
melanoma and ovarian cancer as nonspecific
antigen.
tFor Donors 5 and 6, papain-soluble hepatoma
membranes and normal liver membranes were the
nonspecific control antigens. The third group in
Donor 3 was tested with papain-soluble bowel-
cancer membranes as the nonspecific control
antigens. In the remainder of the preparations, the
control nonspecific antigen was a PBS extract of
either melanoma or ovarian cancer. The presence
of LAI activity is indicated by an NAI value of 30
or more.
t Breast-cancer patient (Br. Ca.), Control (Con.)
or Benign breast disease (Ben. Br.).
LAI assay (Thomson, 1978). To solve this
problem, we have recently used the
blocking tube LAI assay (Grosser and
Thomson, 1976) to detect the presence of
TSA activity (Lopez and Thomson, 1977;
Thomson, 1978). Table III shows that only
the isolated papain-solubilized breast-
cancerantigen (Br .Ca .Ag.) blocks reactive
leucocytes from breast-cancer patients.
Similarly, reactiveleucocytesfrompatients
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TABLE III. Results of Blocking Assayed
by Tube LAI with Papain-Solubilized
TSA Chromatographed on Sephadex
G-150.
NAI* of
Donior of leuco-
leuco- cyte
cytes donor
Breast
cancer
Mlalignant
melanoma
Colonic
cancer
Donor
letuco-
cytes
pre-
incubate(d
with
material
from:
54 Normal
breast tissue
tinboun(d
from DEAE
Fraction 2
Hepatoma
Fractrions 2
4
Melanoma
Fraction 2
Breast cancer
Fractions 1
2
3
4
4
7 1 Breast caincer
Fractions 2
4
Melanoma
Fractions 2
4
58 Breast cancer
Fraction 2
Colonic
cancer
Fraction 2
Proteill
concefn-
trationl
of
blocking
material
(ytg)
400
400
600
600
200
200
200
200
200
100
50
10
100
50
10
600
600
100
100
200
100
25
10
NAI*
after
blocking
5:3
59
39
55
,54
62
-10
:38
--22
28
61
19
'37
66
59
61
-6
5
64
-12
-5
51
*An NAI value of 30 or more iindicates LAI
reactivity.
with melanoma and colon cancer were
blocked only by the papain-soluble mela-
nomaandcolon-cancermembranematerial,
respectively. The results in Table III show
that the amount of material required to
block leucocyte reactivity is more easily
quantitated. By the blocking assay, TSA
activity was measured in 7 different breast-
cancerpreparations andfound to be highest
in Fraction 2. Although activity was detec-
ted in some preparations in Fractions 1, 3
and 4, the antigen activity was usually less
than that in Fraction 2. Similar results
were observed in 3 melanoma and 2
colon-cancer preparations.
Because it was not possible to study all
fractions, in the present study attention
was confined to the material in Fraction 2,
since most TSA activity was in this
fraction and the TSA present was possibly
closer to its native structure.
SDS-PAGE of tumour-antigen prepara-
tions
Fraction 2 from the Sephadex G-150
column was labelled with 125J and electro-
phoresed on 10% SDS gels. The patterns
of the materials from Fraction 2 were very
similar, regardless of tumour type. Fig. 3
shows the 1251 profile on 10% SDS-gels of
papain-soluble breast cancer and melano-
ma material from Fraction 2 of the Sepha-
dex G-150 column. Two major radioactive
peaks with mol. wt of 12,000 and 40,000,
and a relatively minor peak with mol. wt
/25,000 were observed. Similar gel pat-
terns were observed whether or not the
gels were run in the presence or absence
of the reducing agent mercaptoethanol.
Guanidine-HOl chromatography of papain-
soluble tumoar-antigen material
The 1251-labelled papain-soluble breast-
cancer material from Fraction 2 of the
Sephadex CG-150 column, composed of
material of mol. wt 60,000-150,000, was
chromatographed on Sephadex G-200 in
6 M guanidine-HCl and found to consist
of smaller subunits (Fig. 4). Moreover,
smaller subunits were observed when
chromatography was carried out in the
presence or absence of dithiothreitol
(Fig. 4). Fraction 2 from the Sephadex
G-150 column obtained from the papain-
solubilized melanoma material, similarly
chromatographed, resolved into smaller
mol. wt subunits (Fig. 4).
Isolation of papain-soluble tumour antigen
byanti-human-32m affinity chromatography
Since the analysis of the papain-
soluble fractions with tumour-antigen
activity indicated that these molecules
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Fi(e. 3.-Electrophoresis on 10% SDS gel of
1251-labelled breast-cancer material and
melanoma material from chromatographic
Fraction 2 of Sephadex G-150 (Fig. 2). The
mobility of the reduced protein standards
is indicated.
had a macromolecular structure composed
of smaller subunits, one of which was of
mol. wt 12,000, this suggested the
presence of f2m in the preparation, which
was in fact demonstrated in the whole
preparation by radioimmunoassay for
32m. To determine whether the molecule
responsible for the observed tumour-
antigen activity was linked to 32m, the
papain-soluble material from Fraction 2
of the Sephadex G-150 column was
applied to the horse anti-human-12m
affinity column and the bound fractions
eluted with 3M KSCN. The unbound
FIG. 4. Upper figure: 6M guanidine-HCl
chromatographic profile of 1251-labelled
breast-cancer material from chromato-
graphic Fraction 2 of Sephadex G-150;
pattern with 125I-breast cancer material
reduced with dithiothreitol (0) and un-
reduced (A).
Lower figure: 6M guanidine-HCI chrom-
atographic profile of reduced 1251-labelled
malignant-melanoma material from chrom-
atographic Fraction 2 of Sephadex G-150.
The elution positions of the reduced
protein standards are indicated. Each
fraction had a volume of 5 ml.
fraction contained minimal or no f2m,
whereas the bound fraction contained
high levels of 32m, as measured by radio-
immunoassay.
The bound and unbound fractions were
tested against leucocytes from both speci-
fically LAI reactive patients and control
subjects. Table IV shows the LAI response
of melanoma patients and control subjects
to the unbound and bound melanoma
fractions from the anti-32m affinity col-
umn. The leucocytes from the melanoma
patient showed positive LAI reactivity to
the bound melanoma fraction containing
82m, contrasting with the negative reac-
tion of the control subject. Moreover, the
leucocytes of the reactive melanoma
patient showed no LAI reactivity to the
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TABLE IV.-Papain-soluble Melanoma
Membranes Isolated by Anti-Human f2m
Affinity Chromtatography: Antigenic
Activity Assayed by Tube LAI*
P2m Affinity column fractions
Unbound Bound
NAI of_ * ,
donort Pro- Pro-
Leuco- to PBS teinj teint
cyte tumour ,ug/ P2mt ILg/12mt
donor extract tube ng/ml NAI§tubeng/ml NAI§
Malignant 83 50 0 11 50 18 109
melanoma
Malignant 76 50 0 17 50 18 112
melanoma
Control -11 50 0 -26 50 18 -6
Malignant 38 100 0 -5 100 24 33
melanoma
Control -3 100 0 -10 100 24 -19
*Papain-soluble melanoma material was isolated
by Sephadex G-150 chrortatography and Fraction 2
with LAI activity was applied to the anti-human-
92m affinity column.
tMelanoma as specific antigen and with breast
cancer as nonspecific antigen.
$The isolated unbound and bound fractions had
their total protein and 92m content measured by
the Lowry method and fi2m radioimmunoassay,
respectively.
§Papain-soluble melanoma material as the specific
antigen and a PBS extract of breast cancer as the
nonspecific antigen. LAI activity is indicated by an
NAI value of 30 or more.
unbound, /32m free, fraction. Identical
results were observed when leucocytes
from reactive breast-cancer patients and
control subjects were tested against un-
bound and bound papain-soluble breast-
cancer fractions from the anti-32m affinity
column (Table V). Those fractions that
contained /32m and specifically reacted in
the tube LAI assay also contained HLA
antigens, as determined by radioimmuno-
assay.
Initially, the leucocyte reactivity to the
papain-solubilized membrane material
from cancers isolated by anti-32m affinity
chromatography was compared to a non-
specific PBS tumour extract, and Tables
IV and V show that the antigens isolated
from the anti-/32m affinity columns can
replace their equivalent PBS tumour
extract andretain specific antigen activity.
Next, papain-soluble material from hepa-
toma membranes was isolated by anti-
/2m affinity chromatography, and this
TABLE V.-Papain-soluble Breast-cancer
Membranes Isolated by Anti-Human
32m Affinity Chromatography: Antigenic
Activity Assayed by Tube LAI*
f2m Affinity column fractions
Leuco-
cyte
donor
Breast
cancer
Control
Breast
cancer
Control
Breast
cancer
Control
Unbound Bound
NAIt of. A - --)
donor Pro- Pro-
to PBS teint teint
tumour ,ug/ P2mt Kg/ P2mT
extract tube ng/ml NAI§ tubeng/mlNAI§
57 150 0 -28 150 72 80
-18 150 0 -27 150 72 -29
38 100 0 17 100 48 63
-9 100 0
55 30 0
-20 100 48 -28
-17 30 9 48
-18 30 0 -29 30 9 -23
*Papain-soluble breast-cancer material was iso-
lated by Sephadex G-150 chromatography and
tested for LAI activity. Fraction 2 with proven
activity was then fractionated by anti-P2m affinity
chromatography.
tBreast cancer as the specific antigen and ovarian
cancer as the nonspecific antigen.
tTotal content of protein and P2m in the assay
tubes was calculated from that present in the whole
isolated unbound and bound fractions.
§Papain-soluble material as specific antigen and
the PBS extracts ofovarian cancer as the nonspecific
antigen. Presence of LAI activity is indicated by
an NAI value of 30 or more.
material, rather than PBS tumour ex-
tracts, was used as the control antigen in
the tube LAI assay (Table VI). The
leucocytes from the reactive melanoma
patient showed LAI activity against the
bound melanoma fraction from the anti-
f2m affinity column (Table VI). Likewise,
leucocytes of reactive breast patients
displayed LAI activity to the bound
breast-cancer fraction from the anti-/2m
affinity column. Leucocytes from the
melanoma and breast-cancer patients
showed no reactivity to the corresponding
unboundfractions. By contrast, leucocytes
of the control subjects showed no LAI
activity either to the bound or to the
unbound fractions.
A reactive hepatoma patient and a
control subject were tested against the
unbound and bound hepatoma and breast
fractions from the anti-/32m immuno-
adsorbent affinity column (Table VII).
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TABLE VI.-Papain-soluble Melanoma
Antigen and Breast-cancer Antigen Iso-
lated by Anti-Human-32m Affinity Chro-
matography and Assayed by Tube LAI*
82m Affinity
NAI*
of
donor Source
to of
Leuco- PBS papain-t
cyte tumour soluble
donor extract anitigen
Malignant 40
melanoma Melanoma
III
Hepatoma
I
Control 5
Breast 43
cancer
Breast
- Cancer I:
Hepatoma
Control -4
C-
I
*Melanoma and breast can
with a melanoma patient
patient, respectively, and PBE
nonspecific antigen.
tPapain-soluble tumour m,
tographed on Sephadex G-150
specific LAI activity was i
affinity chromatography.
t P2m measured by radioim]
§Melanoma or breast-canc
antigen and the hepatoma isol
antigen. Each assay tube had
Leucocytes from the h
showed LAI reactivity t
and unbound hepatoma:
leucocytes from the co
LAI reactivity. Howe'
TABLE VII.-Papain-soluble Hepatoma
Antigen Isolated by Recycling on Anti-
Human-/32m Affinity Chromatography
and Assayed by Tube LAI.
fl2m Affinity
column fractions NAI* column fractions ________ ___ of ,
Unbound Bound donor Source Unbound Bound to of ^
92m: 92mt Leuco- PBS Papain-t f2m4 p2m:
ng/ nlg/ cyte tumour soluble ng/ ng/
ml NAI§ ml NAI§ donor extract antigen ml NAI§ ml NAI§
-25 75 Hepatoma 42 86 92
Hepatoma
<1 20 II¶ 7 308 Breast
<1 8 cancer 0 150
-19 9 Control 8 28 15
14 45 Hepatoma 42 52 33
Hepatoma
0 100 II** 5 246 Breast
cancer 0 100
<1 8 Control 8 20 0
23 11 After recycling unbound papain-soluble hepatoma material
cer as specific antigen Hepatoma 42' 22 90
and a breast-cancer Hepatoma
3 hepatoma extract as IIT 0 80
F Breast
aterials were chroma- cancer 0 150
), and Fraction 2 with Control -7J 15 -23
isolated by anti-f2m *Hepatoma as specific antigen and breast cancer
as the nonspecific antigen. nunoassay. ttPapain-soluble tumour materials were chroma-
-er isolate as specific tographed on Sephadex G-150 and Fraction 2 with
late as the nonopecific TATas 100e
asprthein.npci LAI activity was isolated by anti-fi2m affinity 100 ,ug protein. chromatography.
tMeasured by radioimmunoassay.
§Soluble hepatoma material as specific antigen
iepatoma patient and breast-cancer material as nonspecific antigen. The unbound fraction and the bound fraction
o both the bound from the 2nd passage of the hepatoma material
fractions, whereas through the anti-fl2m column were tested for LAI
ntrol showed no activity. ¶125Iug/tube. v~er, Table VIII ** 100 ,ug/tube.
shows that, in this instance, the affinity
column was overloaded with 22m-contain-
ing material, so that both the unbound
and bound hepatoma fractions contained
significant quantities of measurable /32m.
The unbound fraction containing /32m
was re-applied to the anti-2m immuno-
adsorbent affinity column andtheunbound
and bound fractions were retested against
the leucocytes from the reactive hepatoma
patient and the control subject. After this
recycling leucocytes from the hepatoma
patient had LAI reactivity only to the
bound fraction containing fl2m and not to
the unbound fraction that was now free of
P22m. Leucocytes from the control subject
showed no LAI reactivity.
To determine if the papain-soluble
cancer antigens bound specifically to the
anti-f2m immunoadsorbent column, pap-
ain-soluble breast-cancer material was
applied to immunoadsorbent columns of
normal IgGfrom bothhumans andrabbits.
About 85% of the material applied to the
columns remained in the unbound frac-
tion, and #77% ofthe material applied was
recovered in the bound fraction by elution
with 3 M KSCN. The unbound material
retained the antigenic activity when
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TABLE VIII.-Results of Application and
Recycling of Papain-Soluble Hepatoma
Antigen on Anti-Human-/2m Affinity
column.
Total
Protein f2m
(mg) (ng)
Applied 59 23,000
Unboun(d 22 1,203
Bound 1.3 32,000
Reapplication of unbound
Applied 19 1,054
Unbound 12 <56
Boundl 1 2 960
assayed by tube LAI, whereas the bound
fraction had no activity (Table IX). In
addition, by f2m radioimmunoassay no
f2m was in the bound fraction, whereas
the unbound fraction had f2m activity
(Table IX).
In the preceding studies (Tables IV, V,
VI and VII) the papain-solubilized mater-
ials from the membranes of cancer cells
isolated by anti-p2m affinity chromato-
graphy were shown to behave similarly
to the PBS cancer extracts, in inhibiting
TABLE IX. Papain-soluble Breast Cancer
Antigen Applied to an Immunoadsorbent
Affinity Column of Normal IgG: Anti-
genic Activity Assayed by Tube LAI§
Affinity column
fractions
NAT of Source Unboundl Bound
donor of
Leuco- to PBS papain-* P2mt f2mT
cyte tumour soluble ng/ ng/
(lonor extract antigen ml NAI § ml NAT §
Breast 42 47 2
cancer
Breast
cancer III 14
Liver 9
0
0
Control -5 -10 7
Control 7 J -13 12
* Papain-soluble materials were chromatographed
on Sephadex G-150 and Fraction 2 with specific LAI
activity was applied to an AH-Sepharose 4B column
linked with normal IgG.
tMeasured by radioimmunoassay.
t Breast cancer as specific antigen and liver as the
nonspecific antigen.
§IgG was from normal human sera. Similar results
were observed when papain-soluble breast-cancer
antigen was passed through an affinity column of
IgG from normal rabbits.
leucocyte adherence to glass in a way that
was immunologically specific. However,
because the standard tube LAI assay is
highly dependent on protein concentra-
tions, the blocking tube LAI was used to
quantitate the purification ofTSA activity
in different tumour preparations from the
anti-/2m column (Table X). The breast-
and colon-cancer and melanoma antigens
isolated by anti-32m affinity column were
consistently able to block at 1 ,ug and, in
some preparations, at 0'5 fig (Table X).
By comparison, Table III shows that,
before purification by anti-32m affinity
chromatography, 50 and 25 ,ug of material
from Fraction 2 of the breast and colon,
respectively, were required to block LAI
reactivity. Table X showsthat theblocking
was immunologically specific, since the
leucocytes of the breast-cancer patient
were not blocked by hepatoma or mela-
noma antigen isolated in the same way
from the anti-32m affinity column. Like-
wise, leucocytes from the melanoma
patient were blocked by melanoma anti-
gen but not by breast- or colon-
cancer antigen, and leucocytes from
the colon-cancer patient were blocked by
the colon-cancer antigen but not by the
melanoma antigen isolated from the anti-
32m affinity column. Leucocytes from 5
breast-cancer patients were tested against
4 breast-cancer preparations with identical
results. Similarly, leucocytes from 3 differ-
ent melanoma patients and 2 colon-cancer
patients were tested against 2 melanoma
and 2 colon-cancer preparations with
identical results. Moreover, the reactivity
of leucocytes to the specific tumour
material that bound to the anti-32m affin-
ity column and the tumour material which
did not bind was highly significant (P<
0*001).
In addition, the binding of the TSA to
the anti-32m affinity column was specific,
since the TSA did not bind to control
affinity columns (Table X). Passage of the
bound material from the anti-32m column
through an anti-NHS column did not
remove the blocking activity, indicating
that the antigen had bound specifically to
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the anti-/32m column (Table X). Similarly,
papain-soluble breast materialfrom Sepha-
dex G-150 Fraction 2 was passaged
through an affinity column of normal
rabbit IgG and the antigen activity was
found in the unbound fraction, indicating
again that binding to the anti-32m column
was specific (Table X).
Also, antisera to non-f32m cell-surface
proteins were raised in rabbits to papain-
TABLE X.-Results of Blocking Assayed
by the Tube LAI After Passage of
Papain-Soluble TSA Through an Anti-
Human-f32m Affinity Column and Control
Columns
Donor
of
leuco-
cytes
NAI
of
leuco-
cyte
donor
Donor
leucocytes
preincubated
with
material
from:
Reactive Anti-human-,2m
Breast affinityfractions of:
Breast cancer
cancer A 38 unbound
bound
B 37 unbound
bound
C 58 bound
D 50 bound
Hepatoma
unbound
bound
Melanoma
unbound
bound
Malignant
melanoma
Breast cancer
A 38 unbound
bound
Breast cancer
B 111 bound
Colonic cancer
bound
Melanoma
unbound
bound
Pro-
tein
concen-
tration
of
block-
ing NAI*
material after
(,ug) blocking
500
100
500
100
100
10
1*0
0*5
100
1
0-5
0-1
500
200
500
200
500
200
100
100
500
100
1.0
0*5
0.1
55
-4
35
7
0
-5
11
34
-7
8
-7
38
52
48
59
43
49
60
84
98
76
23
13
50
63
Table X continued
Donor
of
leuco-
cytes
Colonic
cancer
Breast D
cancer
Malignant
melanoma
C
Breast
cancer
Colonic
cancer
NAI
of
leuco-
cyte
donor
66
Donor
leucocytes
preincubated
with
material
from:
Colonic cancer
unbound
bound
Melanoma
bound
Anti-NHS affinityt
fractions of:
boundfrom
anti-human-,2m
Breast cancer
46 unbound
bound
37 unbound
Normal rabbit IgG
affinityfractions of:
Breast cancer
55 unbound
bound
Anti-non-212m
afftnityfractions of:
Colonic cancer
fraction 2
42 unbound
bound
Pro-
tein
concen-
traction
of
blocking NAI*
material after
(,g) blocking
100 59
100 13
1-0 11
0-5 42
100 52
500 -28
50 35
50 34
100
200
-29
38
50 -4
50 58
*An NAI value of 30 or more indicates LAI re-
activity.
tThe boundpapain-soluble breast-cancer material
from the anti-human-fl2m affinity column was
passaged through an anti-NHS affinity column and
the unbound and bound material was tested for
blocking.
soluble breast-cancer and melanoma mem-
brane material that had not bound to the
horse anti-/32m affinity column. The IgG
(unabsorbed) derived from these antisera
was linked to AH-Sepharose 4B, along
with antiserum to NHS that had been
absorbed on papain-soluble liver-cell mem-
branes linked to AH-Sepharose 4B. On
this column, which had only recently been
prepared, the papain-solubilized TSA of
bowel cancer in Sephadex G-150 Fraction
2 material was shown not to bind, indicat-
ing that antisera prepared to cell-surface
proteins excluding f2m and /32m-linked
proteins does not bind the colon TSA
(Table X).
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TABLE XI.- Protein Yields in Isolation ofPapain-solubilized TSA
Wet weight of tumour
processed (g)
Purified membranes (mg)
Papain-soluble protein (mg)
DEAE chromatography
Sephadex G-150
chromatography (mg)
Preparation
Breast Malignant
cancer melanoma Hepatoma
unbound
(mg)
Fraction
460
4747
425
172
303
2114
208
111
307
2788
147
122
1 44 12 15
2 40 25 27
3 59 39 39
4 46 36 13
Affinity chromatography applied 31 (10,150)* 14 (1,378) 20 (684)
with anti-human-f2m iunbound 18 (0) 8 (144) 7 (80)
(mg) bound 7 (7,200) 5 (1,056) 3 (258)
*In parentheses, quantity of fl2m (ng) in fractions measured by double-antibody radioimmunoassay after
a single passage through the anti-human-fl2m immunoadsorbent column.
The passage of papain-solubilized
tumourmembranefromFraction 2through
the horse anti-/2m affinity column com-
pletely deleted from the material its LAI
activity, associated with a proportionate
loss of the weight of the starting material.
A variable loss of antigenic activity
occurred during the brief exposure to the
3M KSCN, due to denaturation. Also,
the results in Tables VIII and XI indicate
that recovery of the material applied to
the anti-human-32m affinity column was
not complete. The loss was variable and
ranged between 20 and 40%. Typical
yields of materials from each step during
the isolation of the papain-solubilized
TSA are shown in Table XI. The yields
were fairly consistent on each occasion.
Infractions withno 32m, noLAIactivity
was found. On the other hand, free /32m
from urine or normal liver tissue showed
no activity in the tube LAI assay. Hence.
the antigen that is reactive in the LAI is a
molecule that is associated with /2m but
is not fl2m itself. 2m was present in all
fractions from the Sephadex G-150 col-
umn, and the quantity increased in the
lower mol. wt fractions (Fig. 3). Although
Fraction 2 does not have large quantities
of f2m, the tumour-antigen activity
eluted principally in this mol. wt fraction
and was associated with 2m.
SDS-PAGE of material isolated by the
anti-f2mn affinity column
Fig. 5 shows the' 10%-SDS-gel electro-
phoresis profile of 1251-labelled material
from the bound fraction of the anti-/32m
affinity column. Breast cancer, melanoma
and hepatoma material appear to be
composed of 2 major subunits with mol.
wts of ,12,000 and 40,000. A minor
peak was observed at ~25,000. Although
the hepatoma material showed a major
peak between 40,000 to 35,000, it was
diffuse and appeared more heterogeneous
with more or less distinct peaks with mol.
wts of 35,000, 40,000 and 50,000. Also,
the major peak at -40,000 from the
melanoma and breast material showed
heterogeneity. The small irregularities
observed in the contour of the peak were
seen in the same preparation run on
separate occasions, and in different pre-
parations prepared in a similar manner.
To be certain that the materials isolated
from the anti-/2m affinity column were
not substances that had "bled" from the
column, and were subsequently labelled
with 125J, antigenic material to be applied
to the affinity column was prelabelled and
the 1251 profiles of'the material applied,
unbound and bound, were then analysed
by 10% SDS-PAGE. Fig. 6 shows the 125I
profiles. The material bound to the column
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has a similar profile to that when the
material was labelled after elution from the
affinity column. This indicates that con-
tamination by "bleeding" from the column
co
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FrG. 5. SDS-PAGE of the 125I-labelled
Papain-solubilized tumour materials
(breast, melanoma and hepatoma respec-
tively) that bound and were eluted from the
horse anti-human-fl2m affinity column. The
papain-soluble material that bound and was
eluted with 3M KSCN from the affinity
column was shown to have specific LAI
activity. The eluted materials were labelled
with 1251 and run reduced on 10% SDS
gels. The mobility of the reduce(d protein
standards is indicated.
did not, in these instances at least, signifi-
cantly alter the profile on gel electro-
phoresis.
Next, the material run in the SDS-tube
gels was electrophoresed on high-resolu-
tion Laemmli polyacrylamide-SDS slab
gels (0.75 mm thick with a running
gradient of 5 to 20% polyacrylamide) to
Distance Migrated
FIG. 6. The papain-solubilized malignant-
melanoma material from Sephadex G-150
(Fraction 2) was prelabelled with 1251 and
applied to the anti-human-fl2m affinity
column. The SDS-PAGE profiles of the
applied, unbouind and bound materials are
shown.
50
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determine the pattern on staining with cancer material bound and eluted from an
Coomassie blue. Fig. 7 shows the Coomas- immunoadsorbent column ofnormal rabbit
sie-blue SDS-PAGE profile of papain- IgG. Since only small quantities of the
soluble breast-cancer material isolated papain-soluble material adhered to the
from the horse anti-human-32m immuno- control column, it was necessary to con-
adsorbent affinity column. Slot 7 shows centrate the material in contrast to that
the pattern of papain-soluble breast- of the material bound and eluted from the
FIG. 7.-Coomassie blue stain ofisolated papain-soluble breast-cancer material afterPAGE onslabgel
with a 5-20% gradient of polyacrylamide. Slots 3, 4 and 8 show the protein standards (from top
to bottom): phosphorylase (90,000); albumin (68,000); ovalbumin (43,000)); chymotrypsinogen
(25,000); and cytochrome C (12,400). Slot 7: papain-soluble breast-cancer material (Fraction 2)
bound and eluted from an immunoadsorbent column of normal IgG. Slot 1: a preparationof papain-
soluble breast-cancer material bound and eluted from an immunoadsorbent horse anti-human-fl2m.
Slot 2: the same preparation as applied to Slot 1 except the material had been passed through an
immunoadsorbent column of rabbit anti-human-whole-serum. Slots 5 and 6: another preparation of
papain-soluble breast cancer material bound and eluted from an immunoadsorbent column of horse
anti-human-,2m. The gel wasoverloaded to detect minor contaminants and slot 6 had twice as much
protein as Slot 5. The papain-soluble breast-cancer material shown in Slots 1, 2, 5 and 6 had TSA
activity in the tube LAI assay, whereas the material in Slot 7 had no LAI activity.
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horse anti-32m immunoadsorbent affinity
column (Slots 1, 2, 5, 6). In Slot 7, the
most prominent bands are in the mol. wt
ranges 50,000 and 24,000, and probably
represent IgG that has bled from the
control immunoadsorbent column. Analy-
sis of this material by radioimmunoassays
for /2m and HLA revealed no 32m or
xenoantigenic HLA activity; the material
also had no LAI activity. By contrast, a
papain-soluble breast-cancer preparation
bound and eluted from a horse anti-f2m
affinity column is shown in Slots 5 and 6.
Slots 5 and 6 were intentionally over-
loaded with breast-cancer material iso-
lated from the anti-/2m affinity column,
to detect minor contaminants. A major
band with a mobility in the mol. wt range
40,000-43,000 is seen. This band corre-
sponds to the major radiolabelled peak of
,-.40,000 mol. wt observed on the 100o
SDS gels. However, the band stains far
more intensely than would be expected
from the height of the radiolabelled peak,
and suggests that the material is not
readily radiolabelled. By contrast, the
stained band of/2m at -'1 2,000 mol. wt is
barely visible, although a prominent radio-
active peak is observed on SDS gels. Bands
at 25,000 mol. wt are also seen by
Coomassie blue stain and they corre-
spond approximately to the area where
radiolabelled peaks are seen on SDS gels.
A band at -.80,000 mol. wt is shown by
staining on the slab gels but was not
detected on the radiolabelled gels (Figs.
3, 5 and 6). This could represent a small
residual amount of aggregated material
that was not reduced, or an entirely
separate protein moiety. In Slots 1 and 2,
the patterns of yet another preparation
of papain-soluble breast-cancer material
isolated from the horse anti-/2m affinity
column are apparent. In this instance, the
amount ofprotein applied was appropriate
for the capacity of the gels. A prominent
band is present at about 40,000 mol. wt
and the band at 11,000-12,000 mol. wt is
faint. A protein band at -.30,000 is also
prominent. A very faint band is barely
visible at -,80,000 mol. wt. In addition,
the papain-soluble breast-cancer material
run in Slot 2 had been passed through an
immunoadsorbent affinity column of rab-
bit anti-NHS. A comparison of the bands
in Slots 1 and 2 reveals no differences.
Autoradiography of the material in
Slot 2 revealed intense bands at 12,000,
26,000, and 40,000 mol. wt, with the
bands at 12,000 and 26,000 being stronger
than the 40,000 band; other bands were
also seen though they were much fainter
(Fig. 8). The material electrophoresed in
Slot 2, after passage through the rabbit
anti-human-normal-serum affinity column,
retained its antigen activity in the tube
LAI assay (Table X). The breast TSA
isolated from the immunoadsorbent col-
umn of horse anti-human-/2m that gave
the patterns seen in Slots 1, 2, 5 and 6
(Fig. 7) had specific LAI activity when
assayed by the standard and blocking
tube LAI and contained /2m and HLA
xenoantigenic activity by radioimmuno-
assay.
The papain-soluble colon-cancer mater-
ial isolated by anti-32m affinity chromato-
graphy when electrophoresed on the high-
resolution SDS slab gels and stained with
Coomassie blue showed bands at -.12,000,
25,000, 40,000 and 50,000 mol. wt. The
band at 50,000 and a portion of the
material at 25,000 mol. wt probably
represent the H and L chains of IgG that
bled from the column during elution with
3M KSCN. A faint band was also observed
at -65,000 mol. wt. The unbound and
bound papain-soluble colonic-cancer mat-
erial from the anti-non-/2m affinity column
were run on the high-resolution SDS slab
gel and stained with Coomassie blue. In
this instance, the unbound colon material
showed intense bands at -.12,000, 25,000,
and 40,000 mol. wt, whereas the pattern
of the bound material was entirely differ-
ent and lacked these 3 prominent bands.
Xenoantiserum raised to the papain-
solubleBr.Ca.Ag. andabsorbedwithnormal
human serum bound 125J-/2m-Br.Ca.Ag.
and 1251-HLA but not 1251-/2m (Table
XII). After the 1251-HLA or 125-/2m-
Br.Ca.Ag. had been initially precipitated
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FIG. 8. Autoradiograph of isolated papain-
soluble breast-cancer material shown in
Slot 2 of Fig. 7.
with an excess of the xenoantiserum to
either HLA or 32m-Br.Ca.Ag., no addi-
tional material could be subsequently
immunoprecipitated with the other xeno-
antiserum. This indicated that both xeno-
antiserum recognized similar xenoanti-
genic determinants on the heavy chain of
HLA. Next, 1251-fl2m-Br.Ca.Ag. was re-
acted with xenogeneic anti-human 32m,
anti-HLA, anti-32m-Br.Ca.Ag. and nor-
mal rabbit serum, and then Staphylococcus
aureus Cowan 1 was used as a bacterial
adsorbent, as described by Kessler (1975).
The adsorbed immune complexes were
released by boiling for 2 min in 2% SDS
buffer and 2% mercaptoethanol, and the
freed immune complexes were run in SDS
gels by the discontinuous method of
Laemmli (1970). Similar peaks of radio-
activity were observed at '-.40,000, 25,000,
12,000 mol. wt with immune complexes
produced by the xenoantisera to /2m,
HLA and /32m-Br.Ca.Ag. Normal rabbit
serum gave no radiolabelled peaks.
DISCUSSION
In the present study, the standard and
blocking tube LAI assays were used to
monitor the isolation oftumour antigen of
4 different types of human cancer. The
tumour antigen, solubilized from the
tumour cell membranes by papain, was
isolated by techniques routinely used for
TABLE XII.-Results of Binding Studies
withXenoantiseratoCell-surfaceAntigens
% Antigen precipitated:
1251- 125J. 125J- 2m-
Xenoantiseral P2m HLA Br.Ca.Ag.2
Anti-human-fl2m 93 24 46 43
Anti-human-HLA 4 32 51 48
Anti-92m-Br.Ca.Ag. 3 12 28 24
Normal rabbit serum 4 4 12 7
*Used at 1/100 dilution.
tTwo different isolatesofpapain-solubleBr.Ca.Ag.
from anti-human-fl2m affinity column.
$After incubation of 125I-labelled antigen and
xenoantisera overnight at 4VC, an excess (100 ,ul) of
goat anti-rabbit-IgG or goat anti-horse IgG -as
added. Immunes complexes were pelleted by cen-
trifugation at 20,000 g for 20 min, the precipitate
was washed once with PBS and the supernatant
and pellet were counted in a gamma counter.
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purification of human HLA antigens
(Peterson, Rask and Lindblom, 1974).
Immunochemical studies revealed that the
tumour antigen molecules co-isolated with
material indistinguishable physicochemic-
allyfrom HLA antigens, which undoubted-
ly represented the major constituents in
the materials isolated. The TSAs bore a
distinct similarity to normal human HLA
antigens in their linkage to P2m (Peterson
et al., 1974).
In the present study, when the isolated
papain-soluble TSA and reactive leuco-
cytes were from patients with cancers of
similar origin and histology, the papain-
soluble TSA was able to inhibit the glass
adherence of the leucocytes to a greater
extent than papain-soluble TSA or PBS
tumourextractsfrom anunrelatedtumour.
However, the standard tube LAI assay
performed in serum-free medium is highly
dependent on protein concentration (Gros-
ser and Thomson, 1975; Marti and Thom-
son, 1976; Flores et al., 1977; Lopez and
Thomson, 1977; Thomson, 1978) and
titration of the isolated papain-soluble
antigens below 50 ,ug becomes unreliable
because the number of nonadherent cells
is too few to be counted with any consist-
ency. Hence, a blocking tube LAI assay
(Grosser and Thomson, 1976; Lopez and
Thomson, 1977; Thomson, 1978) was used
to quantitate the TSA activity in the
isolates. The advantages of the blocking
tube LAI over the standard tube LAI for
the detection of TSA in tumour isolates
has recently been discussed (Thoinson,
1978). Moreover, in the present study, on
each occasion care was taken to show that
TSA activity detected by either assay was
immunologically specific. Although it ap-
peared highly unlikely that the papain-
soluble TSAs would absorb quantitatively
in a nonspecific fashion to the immuno-
adsorbent column, this possibility was
excluded, since TSA activity was not
removed by immunoadsorbent columns
of either IgG derived from antisera to
non-f2m cell-surface proteins or to NHS
or IgG derived from normal human and
rabbit serum. Similarly, immunoadsorbent
columns used in the isolation of TSA from
the serum of patients with metastatic
breast cancer were shown not to bind the
TSA in a nonspecific manner (Lopez and
Thomson, 1977).
After Sephadex G-150 chromatography,
the majority of the soluble TSA was pre-
sent in the fraction that eluted in the mol.
wt range 70,000-150,000. TSA activity
was present in the excluded fraction;
however, this fraction was not extensively
studied because of the possibility that it
could represent, in part, unsedimented
membrane fragments rather than water-
soluble TSA. TSA activity was detected in
other fractions but usually less frequently
and with less activity. Possible explana-
tions for some variability in the elution
position ofthe papain-soluble TSA may be
related to differences in papain digestion,
the extent of aggregation with storage
and/or the degree of autolysis of original
tumour samples. Hence, in the present
study attention was focused on the further
isolation and characterization of the
material containing TSA activity that
eluted in the mol. wtrange 70,000-150,000.
Analysis of the material with TSA
activity in the 70,000-150,000 mol. wt
range by SDS-PAGE and 6M guanidine-
HCI column chromatography indicated
that the material was composed of smaller
subunits. The presence of a prominent
band on SDS gels at 12,000 mol. wt
suggested that the material contained
P2m, and this was confirmed by /2m radio-
immunoassay of the whole material.
Hence, affinity chromatography with horse
anti-human-/2m was undertaken to deter-
mine whether the TSAs might be asso-
ciated with /2m. The results showed that
the papain-solubilized TSAs from tumours
of 4 different origins and histology bound
specifically totheanti-/2maffinity column.
Analysis of the bound material from the
4 different tumours by SDS-PAGE con-
sistently showed major peaks at about
12,000, 25,000 and 40,000 mol. wt. Thus,
papain-soluble material from the cell
membranes of breast and bowel cancers,
melanoma and hepatoma isolated by
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anti-f2m affinity chromatography have
similar molecular weights and subunit
structures. It is not known, however,
whether the chain that carries the TSA
epitope is on the 25,000 or 40,000 chains;
moreover, it is possible that the chain
carrying the TSA epitope is not visualized
by the SDS gels.
The studies ofNakamuro, Tanigaki and
Pressman (1977) have suggested that 62m
is exclusively conmbined with the HLA
large component, and no other membrane
components are involved in binding /2m.
Likewise, Robb et al. (1976) claim that
detergent-solubilized HLA antigen is
rapidly purified with very little contami-
nation by affinity chromatography with
rabbit anti-human-32m. The fact, there-
fore, that the papain-soluble human TSAs
from breast and bowel cancer, melanoma
and hepatoma bound specifically to the
ant-32m immunoadsorbent suggests that
the TSA determinant is possibly an
integral part of the HLA molecule or al-
ternatively, is physically associated with
the HLA molcule. Moreover, breast
TSA isolated from serum and urine also
co-isolates with HLA antigens and
appears to share the same xenoanti-
genic determinants as present on the
heavy chains of HLA antigens (Lopez and
Thomson, 1977). Obviously, not all the
molecules that are noncovalently linked
with /2m are TSAs since even if the TSA
is eventually proved to be a modified
HLA antigen, it is unlikely that all 4 of
the individual allogeneic molecules would
be altered (Blank and Lilly, 1977).
Not surprisingly, rabbits immunized
with papain-soluble breast-cancer mater-
ial isolated from the anti-/2m affinity
column and containing TSA activity did
not result in the rabbit producing a
reagent that recognized the TSA deter-
minant. Antisera prepared in rabbits, even
to purified HLA antigens, are not likely to
produce reagents of great value in reveal-
ing HLA allospecificity (Sanderson, 1977).
The rabbit can be expected to differ from
man at several places other than the
epitope on the HLA chain, so allospecific
globulins would comprise a minor portion
of the total antibody formed against the
whole alloantigen chain with its attendant
/32m (Sanderson, 1977). Similarly, the
protein chain in humans that carries the
TSA epitope, whatever the origin of the
protein, might be expected to differ from
rabbit at several sites other than the TSA
epitope.
In addition, transplantation antigens
solubilized from normal and neoplastic
tissues with limited papain digestion
demonstrate non-H-2 activity as well as
H-2 activity, as indicated by skin-graft
rejection (Graff and Nathenson, 1971).
Recent biochemical evidence suggests
that the antigenic products ofboth T/t and
H-2 are structurally similar, and t12 has
been reported to be associated with a
/2m-like moiety in the membrane (Artzt
and Bennett, 1975; Michailson et al.,
1977). Similar results have been reported
for the TL antigen (Artzt and Bennett,
1975; Michailson et al., 1977; Ostberg et al.,
1975) which is closely linked to H-2D and
apparently has a reciprocal interaction
with it in the plasma membrane. In
addition, in the region between H-2D and
T/a, genes specify for a cell surface
molecule Qa-2 which is similar to H-2D
in molecular weight and association with
/32m (Michailson et al., 1977). It is sug-
gested that a family of molecules related
by size, subunit structure, genetic linkage,
membrane location and antigenicity may
exist in this area of the chromosome, and
may have arisen from a common ancestral
gene (Michailson et al., 1977). Thus, in
humans, similar non-HLA antigens may
exist and structurally resemble antigens
of the HLA complex; and these non-HLA
antigens could possibly be involved in the
expression of cell-surface TSAs.
Evidence has accumulated, however, to
support the concept that HLA antigens
represent the markers of self-recognition.
The existence of such a mechanism pro-
vides a biological basis for the evolution
of strong transplantation antigen systems,
a known physiological role for which has
been lacking. Doherty, Blanden and
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Zinkernagel (1976) have proposed that the
T cell recognizes an "altered self" antigen
formed by an interaction between H-2
coded structures at the D and K regions
of major histocompatibility complex
(MHC) and the "inducing" antigen. To
date, the data from studies with hapte-
nated cells (Shearer, Rehn and Garbarino,
1975), non-H-2 alloantigens (Bevan, 1975)
including the sex-linked H-Y antigens
(Gordon, Simpson and Samelson, 1975),
viral infected cells (Zinkernagel and
Doherty, 1974) and a haptenated H-2-
deficient tumour line (Forman and Vitetta,
1975) support the altered-self interaction
antigen (Bevan, 1975) adaptor-antigen
complex (Schrader and Edelman, 1976)
hypothesis. Nevertheless, the mechanism
by which antigen associates with MHC-
coded gene products to form the new
altered self or altered antigen is not yet
clear. Moreover, the existence of altered
self antigens has not been shown bio-
chemically.
Human TSAs could possibly be of 3
different origins:
1. The TSA could be a modified MHC-
coded structure;
2. The TSA could be spatially linked
with the HLA antigens but on independ-
ently coded molecules with the HLA mole-
cules serving as adaptors that combine
with anitigens on the cell surface to form
hybrid antigens containing elements of
self(HLA) andnon-self(TSA) (Ohno, 1977;
Schrader, Cunningham and Edelman,
1975). In this context, however, a pre-
liminary examination of our breast-cancer
tumoutr isolates for associated murine
mammary-tumour viral antigens have
given negative results;*
3. TSA could be a molecule that is un-
related to HLA antigens and is expressed
* Our anti-fl2m-Br.Ca.Ag. serum does not pre-
cipitate any of the MMTV polypeptides, and the
radiolabelled fl2m-Br.Ca.Ag. was not precipitable
with antisera to MMTV polypeptides. The cold
212m-Br.Ca.Ag. did not inhibit radiolabelled virus in
RIA; if putative MMTV antigen was present, the
concentration was <1 ng/50 1l. These studies were
kindly performed for us by Dr R. D. Cardiff, Dept.
of Pathology, University of California, School of
Medicine, Davis, California.
separately on the cell surface, but may
share some xenoantigenic determinants
and/or structural features with the HLA
antigens.
The data from our studies are insuffi-
cient to determine which, if any, of the
above possibilities is correct. Neverthe-
less, the results of the present study
provide a unified approach to the isolation
of human TSA from cancers arising in
different organs.
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